Harvard, MIT Again Win Right to CRISPR Tech Over Nobel Laureates

The Patent Trial and Appeal Board ruled that a March 2012 lab notebook entry and a subsequent provisional patent by Nobel laureates did not demonstrate conception of all elements needed to claim priority to CRISPR-Cas9, leaving an issued patent with the Broad Institute intact. The order undermines competing MIT/Harvard researchers' ownership claims to a potentially multimillion-dollar gene-editing technology and could influence valuations of CRISPR-focused companies.

Analysis

This PTAB outcome tightens the effective patent corridor around key CRISPR implementations, concentrating negotiating leverage and future royalty streams into entities aligned with the upheld patent family. Over the next 6–24 months, expect consolidation in licensing deals and a two-tier market where platform-agnostic or alternative-editing technologies (base editors, prime editors, delivery platforms) see relative rerating versus pure-play Cas9-dependent developers.

Capital markets will start to price in litigation carry — meaning smaller developers with single-product CRISPR bets face higher discount rates and funding stress; conversely, institutions holding Broad-aligned IP exposure gain optionality to monetize via sublicenses or enforcement. The appeals timeline and any Federal Circuit decision are the principal macro catalysts: a quick upholding crystallizes recurring revenue (multi-year tail), whereas a reversal re-opens broad freedom-to-operate and compresses licensor margins.

Operationally, expect downstream effects on CROs, viral vector suppliers, and CDMOs: customers of companies facing infringement risk will postpone scale-up capex or demand indemnities, shifting near-term demand patterns away from capital-intensive manufacturing. That creates a 9–18 month window where service providers with diversified client bases outperform those concentrated in at-risk CRISPR therapeutics.

Key Decisions for Investors

• Initiate a 12–24 month tactical long on Broad-aligned license beneficiaries (e.g., EDIT) via 9–15 month call spreads to limit premium; target position size 1–2% of portfolio. Rationale: crystallizing patent holder leverage creates recurring licensing optionality; downside is legal appeal (payoff asymmetric if sublicensing deals announced).
• Establish a small core underweight (or buy 9–18 month puts) on pure-play Cas9-dependent developers (CRSP, NTLA) sized 0.5–1% each as hedge against higher royalty burdens and delayed commercial rollouts. Risk: technological workarounds or successful appeals could trigger sharp mean reversion — cap position size accordingly.
• Pair trade: long a diversified editor (BEAM) or delivery-focused name (TMO/IDXX-equivalents for reagents) and short a single-tech CRISPR therapeutics name for a 6–18 month horizon. Expect resilience from non-Cas9 modalities and reagent/service firms while single-tech players reprice for legal risk.
• Monitor catalyst triggers (Federal Circuit docket entries, licensing announcements, major M&A of university spinouts) and plan to add to longs on confirmed sublicensing deals or take profits if an appeal clears freedom-to-operate within 6–12 months.